BioPharma articles

Top 10 Stocks Holdings Of Larry Robbin

Top 10 Stocks Holdings Of Larry Robbin

Top 10 Stocks Holdings Of Larry Robbin

The 51 years old Billionaire Larry Robbins witnessed tough times at his firm, popularly known as Glenview Capital Management. At times, he had to struggle hard for business. He is among those hedge fund planners who stressed on the need that drastic changes are required to upgrade the US healthcare system. The reputation of Larry

15 Advantages and Disadvantages of Genetically Modified Organisms

Is genetically modified food really that bad for us? Why are people so afraid of it? Learn more about it on Insider Monkey. These 15 advantages and disadvantages of genetically modified organisms remain a highly controversial topic, despite all the research that has been conducted on the subject. The debate on genetically modified organisms often resembles the one

Amgen, Inc. (AMGN) Surpassed Market Expectations, Thrives On Better Sales And Revenue Figures

It was an excellent quarter for the world’s largest biotechnology company, Amgen, Inc. (NASDAQ:AMGN), as it posted a better than expected fourth quarter 2014 and fiscal 2014 financial results. Enbrel® was the primary reason for the growth in sales and revenues of the biotech company along with additional tax credit. The biotechnology company announced its

Google Inc (GOOGL) X Labs Inks Accord with Biogen Idec Inc (BIIB) for Multiple Sclerosis Initiative

Google Inc (NASDAQ:GOOGL) is teaming up with global biotech firm Biogen Idec Inc (NASDAQ:BIIB) for an extensive research initiative in the field of multiple sclerosis. Biogen is popular for its array of various drugs for multiple sclerosis, and has announced early this year about a revolutionary drug that can repair nerve damage in patients suffering

Merck & Co., Inc (MRK) Responds to Superbugs Challenge with Cubist Acquisition

Merck & Co., Inc. (NYSE:MRK) is aiming to take a lead in responding to the global health challenge that the so-called “superbugs” are posing to modern medicine with its planned acquisition of antibiotics firm Cubist Pharmaceuticals Inc (NASDAQ:CBST). The buy-out deal, estimated to be worth $8.4 billion to $9.5 billion, was announced on Monday, and

Agios Pharmaceuticals Inc (AGIO), United Technologies Corp (UTX) on ‘Buy/Watch’ List

If you are an American investor who is confused about what to look for next week, Jim Cramer would turn out to be your best friend, philosopher and guide, especially after the number of recommendations which he made on CNBC on Friday, 5th December, 2014. Amongst the several stocks which he mentioned on a day-to-day

Merck & Co. Inc (MRK) Set to Acquire Cubist Pharmaceuticals Inc (CBST) for $7 Billion

Merck & Co., Inc. (NYSE:MRK) is looking forward to acquiring Cubist Pharmaceuticals Inc (NASDAQ:CBST), an antibiotics maker, in a deal estimated to cost about $7 billion to $8 billion. A report by the Financial Times cited an unnamed source as saying that Merck will be paying Cubist around $102 per  share, with official announcements expected

Johnson & Johnson (JNJ) Likely To Dispose Artificial Sweetener Unit Amid Weaker Soft Drink Sales

Johnson & Johnson (NYSE:JNJ), one of the largest healthcare companies of the world, is likely to toss out its artificial sweetener unit amid falling soft drink sales. The healthcare company is working with Goldman Sachs Group Inc (NYSE:GS) to find out potential options for the sale of its sweetener unit. Splenda is an artificial sweetener